Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Dunn

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Biotechnology and Bioengineering|February 1, 2023
Accelerated cell culture process development and characterization for cilgavimab/tixagevimab (AZD7442) for the prevention and treatment of COVID-19Michael W Handlogten, Stefanie Bosley, Sarah Dunn, et al.
The Lancet Regional Health. Europe|January 19, 2026
Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trialAndrew Bryant, Jan Lecouturier, Giovany Orozco-Leal, et al.
Mabs|February 26, 2026
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHORajesh K Mistry, Chendi Nui, Giulia Lambiase, et al.
BMJ Open|June 17, 2025
Carbon footprint of a sample of clinical trials for people with neurological disorders: cross-sectional analysisDenise Cranley, Sarah Dunn, John-Paul Taylor, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 22, 2020
Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Cluster-Randomized TrialJohn T O'Brien, Ian G McKeith, Alan J Thomas, et al.
Journal of Biotechnology|March 2, 2020
A platform for context-specific genetic engineering of recombinant protein production by CHO cellsJoseph F Cartwright, Claire L Arnall, Yash D Patel, et al.
Health Technology Assessment (Winchester, England)|March 3, 2026
Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm studyAndrew Bryant, Jan Lecouturier, Giovany Orozco-Leal, et al.
Trials|June 5, 2016
Antibiotic treatment for intermittent bladder catheterisation with once daily prophylaxis (the AnTIC study): Study protocol for a randomised controlled trialCatherine Brennand, Alexander von Wilamowitz-Moellendorff, Sarah Dunn, et al.
The Lancet. Digital Health|June 30, 2023
Patient emergency health-care use before hospital admission for COVID-19 and long-term outcomes in Scotland: a national cohort studyAnnemarie B Docherty, James Farrell, Mathew Thorpe, et al.
BMJ Open|March 11, 2026
Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acidSarah Dunn, Lysbeth Evans, Ciara Kennedy, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Biotechnology and Bioengineering|February 1, 2023
Accelerated cell culture process development and characterization for cilgavimab/tixagevimab (AZD7442) for the prevention and treatment of COVID-19Michael W Handlogten, Stefanie Bosley, Sarah Dunn, et al.
The Lancet Regional Health. Europe|January 19, 2026
Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trialAndrew Bryant, Jan Lecouturier, Giovany Orozco-Leal, et al.
Mabs|February 26, 2026
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHORajesh K Mistry, Chendi Nui, Giulia Lambiase, et al.
BMJ Open|June 17, 2025
Carbon footprint of a sample of clinical trials for people with neurological disorders: cross-sectional analysisDenise Cranley, Sarah Dunn, John-Paul Taylor, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 22, 2020
Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Cluster-Randomized TrialJohn T O'Brien, Ian G McKeith, Alan J Thomas, et al.
Journal of Biotechnology|March 2, 2020
A platform for context-specific genetic engineering of recombinant protein production by CHO cellsJoseph F Cartwright, Claire L Arnall, Yash D Patel, et al.
Health Technology Assessment (Winchester, England)|March 3, 2026
Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm studyAndrew Bryant, Jan Lecouturier, Giovany Orozco-Leal, et al.
Trials|June 5, 2016
Antibiotic treatment for intermittent bladder catheterisation with once daily prophylaxis (the AnTIC study): Study protocol for a randomised controlled trialCatherine Brennand, Alexander von Wilamowitz-Moellendorff, Sarah Dunn, et al.
The Lancet. Digital Health|June 30, 2023
Patient emergency health-care use before hospital admission for COVID-19 and long-term outcomes in Scotland: a national cohort studyAnnemarie B Docherty, James Farrell, Mathew Thorpe, et al.
BMJ Open|March 11, 2026
Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acidSarah Dunn, Lysbeth Evans, Ciara Kennedy, et al.
Pageof 5